Bertrand Anz

1.2k total citations · 1 hit paper
20 papers, 543 citations indexed

About

Bertrand Anz is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Bertrand Anz has authored 20 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 11 papers in Hematology and 9 papers in Oncology. Recurrent topics in Bertrand Anz's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Bertrand Anz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Bertrand Anz collaborates with scholars based in United States, Canada and Spain. Bertrand Anz's co-authors include Ian W. Flinn, Carol Moreno, Fatih Demırkan, Martin Šimkovič, Devinder Gill, John G. Gribben, Loree Larratt, Alessandra Tedeschi, Richard Greil and Jan Novák and has published in prestigious journals such as Blood, The Lancet Oncology and Haematologica.

In The Last Decade

Bertrand Anz

20 papers receiving 536 citations

Hit Papers

Ibrutinib plus obinutuzumab versus chlorambucil plus obin... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bertrand Anz United States 7 472 391 171 168 103 20 543
Владимир Стругов Russia 4 466 1.0× 392 1.0× 124 0.7× 167 1.0× 63 0.6× 12 485
Ulrike Söling Germany 8 447 0.9× 380 1.0× 126 0.7× 201 1.2× 81 0.8× 16 525
Manuela A. Bergmann Germany 6 562 1.2× 502 1.3× 104 0.6× 239 1.4× 55 0.5× 11 592
Sandra Robrecht Germany 12 415 0.9× 360 0.9× 98 0.6× 203 1.2× 75 0.7× 45 496
R. F. Bezares Argentina 3 516 1.1× 438 1.1× 97 0.6× 250 1.5× 72 0.7× 5 555
Ghayathri Jeyakumar United States 4 283 0.6× 253 0.6× 89 0.5× 125 0.7× 106 1.0× 9 388
Julia von Tresckow Germany 9 333 0.7× 303 0.8× 92 0.5× 128 0.8× 49 0.5× 35 391
Polina Kaplan Poland 6 283 0.6× 228 0.6× 116 0.7× 94 0.6× 59 0.6× 9 331
Tamia Nguyen Australia 7 328 0.7× 204 0.5× 175 1.0× 109 0.6× 77 0.7× 15 465
Yoonjin Cho United States 8 378 0.8× 327 0.8× 83 0.5× 98 0.6× 141 1.4× 16 480

Countries citing papers authored by Bertrand Anz

Since Specialization
Citations

This map shows the geographic impact of Bertrand Anz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Anz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Anz more than expected).

Fields of papers citing papers by Bertrand Anz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Anz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Anz. The network helps show where Bertrand Anz may publish in the future.

Co-authorship network of co-authors of Bertrand Anz

This figure shows the co-authorship network connecting the top 25 collaborators of Bertrand Anz. A scholar is included among the top collaborators of Bertrand Anz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertrand Anz. Bertrand Anz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274. 6 indexed citations
2.
Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2023). MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S494–S495. 1 indexed citations
3.
4.
5.
6.
7.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265. 3 indexed citations
8.
Greil, Richard, Alessandra Tedeschi, Carol Moreno, et al.. (2021). Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Annals of Hematology. 100(7). 1733–1742. 9 indexed citations
9.
Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2021). Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study. Blood. 138(Supplement 1). 3725–3725. 1 indexed citations
10.
Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations
11.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2020). Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial. Blood. 136(Supplement 1). 16–17. 3 indexed citations
12.
Sharman, Jeff P., David Andorsky, Jason M. Melear, et al.. (2020). CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 20. S219–S220. 1 indexed citations
13.
Yardley, Denise A., William H. Liggett, Mark Mainwaring, et al.. (2019). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer. 20(2). 89–97. 6 indexed citations
14.
Sharman, Jeff P., David Andorsky, Jason M. Melear, et al.. (2019). Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study. Blood. 134(Supplement_1). 3042–3042. 4 indexed citations
15.
Tedeschi, Alessandra, Carol Moreno, Bertrand Anz, et al.. (2019). IBRUTINIB DECREASES OBINUTUZUMAB‐INDUCED SECRETION OF CYTOKINES ASSOCIATED WITH INFUSION‐RELATED REACTIONS IN PATIENTS WITH CLL: ANALYSIS FROM THE ILLUMINATE STUDY. Hematological Oncology. 37(S2). 210–212. 3 indexed citations
16.
17.
Moreno, Carol, Richard Greil, Fatih Demırkan, et al.. (2018). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(1). 43–56. 380 indexed citations breakdown →
18.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2018). Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure. Blood. 132(Supplement 1). 3271–3271. 5 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Владимир Стругов Breakdown of academic impact, for papers by Ulrike Söling Breakdown of academic impact, for papers by Manuela A. Bergmann Breakdown of academic impact, for papers by Sandra Robrecht Breakdown of academic impact, for papers by R. F. Bezares Breakdown of academic impact, for papers by Ghayathri Jeyakumar Breakdown of academic impact, for papers by Julia von Tresckow Breakdown of academic impact, for papers by Polina Kaplan Breakdown of academic impact, for papers by Tamia Nguyen Breakdown of academic impact, for papers by Yoonjin Cho
Rankless by CCL
2026